BoltzOmics: Predicting genetic variant effects on drug binding with Boltz-2

A mechanistic understanding of how genetic variants alter drug-receptor binding is central to precision medicine, drug response prediction, and drug development. Yet, experimental mutation-drug profiling remains slow and expensive, while existing computational approaches often trade accuracy for scalability. We developed BoltzOmics, an interactive, open-source platform that integrates Boltz-2, a deep learning model for biomolecular structure prediction, to rapidly assess mutation effects on drug binding. Starting from amino acid sequences, the workflow queries databases for genetic variants, generates wild-type and mutant protein structures, and screens multiple drugs across variants to predict binding affinity changes. We evaluated BoltzOmics across four targets: hERG, Na V 1.5, HER2, and CYP3A4. Predictions achieved Pearson correlations with experimental drug IC 50 data up to 0.76 for wild-type proteins and 0.60 for mutants. By enabling scalable, high-throughput assessment of drug-variant interactions, BoltzOmics establishes a practical AI-driven framework for accelerating computational drug discovery and advancing precision medicine research.